Myo - Inositol in women with PCOS

 

Myo – Inositol has demonstrated in combination with Folic Acid (the Vitamin B6) in clinical studies a significant improvement in testosterone, triglyceride and insulin levels (source: 1), factors associated with Polycystic Ovarian Syndorme (PCOS). The product called INOCAPS® can be used three caps daily.

 

PCOS is one of the most common endocrine disorders in women and affects up to 20% of women of reproductive age (source: 2). Women showing features of this syndrome are often diagnosed with chronic oligomenorrhea or anovulation, hyperandrogenism and show a polycystic ovarian morphology (source: 3) .

 

 

 

 

 

 

 

 

 

 

 

 

 

It is not simply the ovarian abnormality that contributes to problems like abnormal cycles or even infertility. PCOS is associated with an increased risk of developing severe diseases like diabetes (source: 4) and heart diseases (source: 5). And PCOS is associated with insulin resistance in both, overweight and lean women (source: 6). Myo - Inositol, is a natural insulin sensitizer and can help restore a deficiency of intracellular metabolites in women with PCOS (source: 7). In addition to its role as insulin sensitizer, Myo - Inositol plays an important role in the follicular milieu, meiotic resumption and oocyte maturation as an intracellular messenger in mammalian oocytes (source: 8).

 

A clinical study has shown that women treated with Myo – Inositol in combination with Folic Acid (product called INOCAPS®) had reduced androgen levels, helped restore ovulatory function, lowered blood pressure and decreased triglyceride levels (source: 1). This study confirms prior studies that have shown that Myo - Inositol administration improves endocrine parameters and insulin sensitivity. Myo - Inositol is a safe and effective natural medicine for improving insulin resistance (source: 9). Myo - Inositol should be recommended in conjunction with other positive lifestyle modifications like weight loss and dietary interventions for the management of PCOS and insulin resistance (source: 10).

 

The combination of Myo – Inositol and Folic Acid has proven

its important role at improving PCOS.

 

 

 

 

 

 

 

 

 

 

 

 

Sources:

1.  Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7(6):151–159)

2.  Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9): 3078–3082)

3.  Rotterdam ESHRE/ASRM-Sponsored PCOS wonsensus workshop group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47)

4. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in PCOS: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab.1999;84(1):165–169)

5. Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):803–812)

6. Zawadsky JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Current Issues in Endocrinology and Metabolism: PCOS. Cambridge, UK: Blackwell Scientific Publications; 1992: 377–384)

7.  Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo - Inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, Gynecol Endocrinol. 2008;24:139–144)

8. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ: Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002;17(6):1591–1596)

9.  Carlomagno G, Unfer V: Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–936)

10.  Setareh Tais, ND, Myo - Inositol in Polycystic Ovarian Syndrome, (http://naturalmedicinejournal.com/journal/2013-08/myo-inositol-polycystic-ovarian-syndrome).